The importance of supplementary immunisation activities to prevent measles outbreaks during the COVID-19 pandemic in Kenya.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
03 02 2021
Historique:
received: 14 10 2020
accepted: 11 01 2021
entrez: 3 2 2021
pubmed: 4 2 2021
medline: 12 2 2021
Statut: epublish

Résumé

The COVID-19 pandemic has disrupted routine measles immunisation and supplementary immunisation activities (SIAs) in most countries including Kenya. We assessed the risk of measles outbreaks during the pandemic in Kenya as a case study for the African Region. Combining measles serological data, local contact patterns, and vaccination coverage into a cohort model, we predicted the age-adjusted population immunity in Kenya and estimated the probability of outbreaks when contact-reducing COVID-19 interventions are lifted. We considered various scenarios for reduced measles vaccination coverage from April 2020. In February 2020, when a scheduled SIA was postponed, population immunity was close to the herd immunity threshold and the probability of a large outbreak was 34% (8-54). As the COVID-19 contact restrictions are nearly fully eased, from December 2020, the probability of a large measles outbreak will increase to 38% (19-54), 46% (30-59), and 54% (43-64) assuming a 15%, 50%, and 100% reduction in measles vaccination coverage. By December 2021, this risk increases further to 43% (25-56), 54% (43-63), and 67% (59-72) for the same coverage scenarios respectively. However, the increased risk of a measles outbreak following the lifting of all restrictions can be overcome by conducting a SIA with ≥ 95% coverage in under-fives. While contact restrictions sufficient for SAR-CoV-2 control temporarily reduce measles transmissibility and the risk of an outbreak from a measles immunity gap, this risk rises rapidly once these restrictions are lifted. Implementing delayed SIAs will be critical for prevention of measles outbreaks given the roll-back of contact restrictions in Kenya.

Sections du résumé

BACKGROUND
The COVID-19 pandemic has disrupted routine measles immunisation and supplementary immunisation activities (SIAs) in most countries including Kenya. We assessed the risk of measles outbreaks during the pandemic in Kenya as a case study for the African Region.
METHODS
Combining measles serological data, local contact patterns, and vaccination coverage into a cohort model, we predicted the age-adjusted population immunity in Kenya and estimated the probability of outbreaks when contact-reducing COVID-19 interventions are lifted. We considered various scenarios for reduced measles vaccination coverage from April 2020.
RESULTS
In February 2020, when a scheduled SIA was postponed, population immunity was close to the herd immunity threshold and the probability of a large outbreak was 34% (8-54). As the COVID-19 contact restrictions are nearly fully eased, from December 2020, the probability of a large measles outbreak will increase to 38% (19-54), 46% (30-59), and 54% (43-64) assuming a 15%, 50%, and 100% reduction in measles vaccination coverage. By December 2021, this risk increases further to 43% (25-56), 54% (43-63), and 67% (59-72) for the same coverage scenarios respectively. However, the increased risk of a measles outbreak following the lifting of all restrictions can be overcome by conducting a SIA with ≥ 95% coverage in under-fives.
CONCLUSION
While contact restrictions sufficient for SAR-CoV-2 control temporarily reduce measles transmissibility and the risk of an outbreak from a measles immunity gap, this risk rises rapidly once these restrictions are lifted. Implementing delayed SIAs will be critical for prevention of measles outbreaks given the roll-back of contact restrictions in Kenya.

Identifiants

pubmed: 33531015
doi: 10.1186/s12916-021-01906-9
pii: 10.1186/s12916-021-01906-9
pmc: PMC7854026
doi:

Substances chimiques

Measles Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : Medical Research Council
ID : MC_PC_19065
Pays : United Kingdom
Organisme : Medical Research Council, Department for International Development
ID : MR/S005293/1

Investigateurs

James D Munday (JD)
Carl A B Pearson (CAB)
Simon R Procter (SR)
Oliver Brady (O)
David Simons (D)
Rachel Lowe (R)
W John Edmunds (WJ)
Katharine Sherratt (K)
Rosanna C Barnard (RC)
Alicia Rosello (A)
Adam J Kucharski (AJ)
Fiona Yueqian Sun (FY)
Nikos I Bosse (NI)
Petra Klepac (P)
Yang Liu (Y)
Kiesha Prem (K)
Gwenan M Knight (GM)
Akira Endo (A)
Sam Abbott (S)
Emily S Nightingale (ES)
Thibaut Jombart (T)
Jon C Emery (JC)
Georgia R Gore-Langton (GR)
Joel Hellewell (J)
James W Rudge (JW)
Hamish P Gibbs (HP)
Kathleen O'Reilly (K)
Kevin van Zandvoort (K)
Yung-Wai Desmond Chan (YD)
Damien C Tully (DC)
Anna M Foss (AM)
Christopher I Jarvis (CI)
Katherine E Atkins (KE)
Samuel Clifford (S)
Matthew Quaife (M)
Billy J Quilty (BJ)
Rein M G J Houben (RMGJ)
Rosalind M Eggo (RM)
Graham Medley (G)
Sophie R Meakin (SR)
Timothy W Russell (TW)
Nicholas G Davies (NG)
Charlie Diamond (C)
Arminder K Deol (AK)
C Julian Villabona-Arenas (CJ)
Stéphane Hué (S)
Megan Auzenbergs (M)
Quentin J Leclerc (QJ)
Amy Gimma (A)

Références

PLoS One. 2014 Aug 15;9(8):e104786
pubmed: 25127257
BMC Med. 2020 Oct 5;18(1):316
pubmed: 33012285
Lancet Glob Health. 2020 Oct;8(10):e1264-e1272
pubmed: 32687792
Clin Vaccine Immunol. 2012 Mar;19(3):396-400
pubmed: 22237896
J Infect Dis. 2011 Jul;204 Suppl 1:S343-52
pubmed: 21666183
Int J Infect Dis. 2014 Feb;19:103-5
pubmed: 24334025
Vaccine. 2018 Jan 2;36(1):170-178
pubmed: 29174680
Vaccine. 2018 Dec 18;36(52):7965-7974
pubmed: 30416017
Pan Afr Med J. 2018 Sep 28;31:65
pubmed: 31007812
PLoS One. 2018 Jul 2;13(7):e0199786
pubmed: 29965975
BMC Med. 2019 Sep 25;17(1):180
pubmed: 31551070
Science. 2015 Mar 13;347(6227):1240-2
pubmed: 25766232
Vaccine. 2018 Feb 28;36(10):1248-1255
pubmed: 29398276
J Res Med Sci. 2015 May;20(5):529-30
pubmed: 26487883
Int J Epidemiol. 2012 Jun;41(3):650-7
pubmed: 22544844
Lancet Infect Dis. 2020 May;20(5):546
pubmed: 32311326
Lancet Infect Dis. 2019 Nov;19(11):1235-1245
pubmed: 31548079
Int J Epidemiol. 2010 Apr;39 Suppl 1:i48-55
pubmed: 20348126
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186

Auteurs

C N Mburu (CN)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. CMburu@kemri-wellcome.org.
Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. CMburu@kemri-wellcome.org.

J Ojal (J)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

R Chebet (R)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

D Akech (D)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

B Karia (B)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

J Tuju (J)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

A Sigilai (A)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.

K Abbas (K)

Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

M Jit (M)

Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

S Funk (S)

Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

G Smits (G)

Department of Immunosurveillance, Centre for Infectious Diseases Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

P G M van Gageldonk (PGM)

Department of Immunosurveillance, Centre for Infectious Diseases Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

F R M van der Klis (FRM)

Department of Immunosurveillance, Centre for Infectious Diseases Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

C Tabu (C)

National Vaccine and Immunisation Programme, Ministry of Health, Nairobi, Kenya.

D J Nokes (DJ)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
School of Life Sciences and Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, Coventry, UK.

Jag Scott (J)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

S Flasche (S)

Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.

Imo Adetifa (I)

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. IAdetifa@kemri-wellcome.org.
Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. IAdetifa@kemri-wellcome.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH